Search clinical trials for: T memory cells and NK cells

Total 7614 results

KK Women's and Children's Hospital
Singapore General Hospital

Recruiting

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | B-cell Acute Lymphoblastic Leukemia | Large B-cell Lymphoma

Singapore
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
King's College Hospital NHS Trust

Recruiting

Autologous Tregs for Aplastic Anaemia (TIARA)

Aplastic Anemia

United Kingdom
Fudan University
KAEDI

Recruiting

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Glioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon Cancer

China
AffyImmune Therapeutics, Inc.

Recruiting

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Anaplastic Thyroid Cancer | Relapsed/Refractory Poorly Differentiated Thyroid Cancer

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Acute Myeloid Leukemia

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Plasmacytoid; Lymphoma

China
Xuanwu Hospital, Beijing
Beijing Mario Biotech Company; Hebei Senlang BIotech Company; Beijing HuiNengAn...

Recruiting

Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

Glioma | Malignant Glioma of Brain | Recurrence Tumor

China
Poitiers University Hospital

Active, not recruiting

Innate T Cells and TKI Discontinuation (TIBIOP-LMC)

Chronic Myeloid Leukemia

France
Memorial Sloan Kettering Cancer Center

Active, not recruiting

MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Active, not recruiting

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

China
Sinobioway Cell Therapy Co., Ltd.
The Second Hospital of Anhui Medical University

Active, not recruiting

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (EECNTL)

Leukemia

China
Fujian Medical University

Unknown

CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

Relapsed/Refractory AML

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Shenzhen Geno-Immune Medical Institute

Unknown

Antigen-specific T Cells Against Lung Cancer

Lung Cancer

China
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co, Ltd. China

Unknown

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | NK/T-cell Lymphoma | Adult T-Cell Lymphoma/Leukaemia

China
Eureka Therapeutics Inc.
Duke University; Duke Clinical Research Institute

Terminated

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

Lymphomas Non-Hodgkin's B-Cell

United States
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy

Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI

China
Qingdao Central Hospital
Yake Biotechnology Ltd.

Unknown

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-Cell | Minimal Disease, Residual

China
Sinobioway Cell Therapy Co., Ltd.

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer (EECSC)

Stomach Neoplasms

China
Roger Williams Medical Center

Suspended

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

Monitor Adverse Events

United States
Peking University
University of Florida

Unknown

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Lymphomas

China, United States
H. Kim Lyerly
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease (CMV-BMT)

Allogeneic Stem Cell Transplantation

United States
VIRxSYS Corporation

Active, not recruiting

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

HIV Infection

United States
Wuhan Union Hospital, China

Not yet recruiting

Study of SYS6020 in BCMA-positive Multiple Myeloma

Multiple Myeloma
The Children's Hospital of Zhejiang University...
Chongqing Precision Biotech Co., Ltd

Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | CAR-T Cell Therapy

China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
University of Pennsylvania
Prostate Cancer Foundation

Recruiting

TmPSMA-02 in mCRPC

Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | T Lymphoblastic Leukemia/Lymphoma

China
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; The Affiliated Nanjing Drum Tower... and other collaborators

Recruiting

CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma

Refractory and Relapsed T Cell Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

Gastric Cancer | Lung Cancer | Osteosarcoma | Neuroblastoma
iCell Gene Therapeutics
The General Hospital of Western Theater Command; Peking University Shenzhen... and other collaborators

Recruiting

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Rapa Therapeutics LLC
Massachusetts General Hospital; Hackensack Meridian Health

Available

RAPA-501 Therapy for ALS EAP

Amyotrophic Lateral Sclerosis

United States
Children's Hospital Medical Center, Cincinnati
Hoxworth Blood Center

Active, not recruiting

Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant

Solid Organ Transplant | Viral Infection

United States
University of Pennsylvania

Completed

cMet CAR RNA T Cells Targeting Breast Cancer

Metastatic Breast Cancer | Triple Negative Breast Cancer

United States
Children's Hospital Medical Center, Cincinnati
Hoxworth Blood Center

Withdrawn

Viral Specific T-cells for Treatment of COVID-19

Viral Infection

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Lymphoma, B-Cell | Leukemia, B-cell

China
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co., Ltd.

Unknown

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Xinqiao Hospital of Chongqing
Xuzhou Medical University; Shanghai Changzheng Hospital; Hrain Biotechnology...

Unknown

Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma (MeCAR)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III Follicular Lymphoma | Stage...

China
Shanghai Tongji Hospital, Tongji University School...

Unknown

CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy

Lymphoma | Leukemia

China
Cell Medica Ltd
University College, London; Cell Therapy Catapult

Completed

WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

Acute Myeloid Leukaemia | Chronic Myeloid Leukaemia

United Kingdom
Sinobioway Cell Therapy Co., Ltd.

Unknown

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

Lymphoma

China
Sinobioway Cell Therapy Co., Ltd.
The First Affiliated Hospital of Anhui Medical University

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma (EECBL)

Lymphoma

China
Sinobioway Cell Therapy Co., Ltd.
Children's Hospital of Fudan University; Nanjing Children's Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Relapsed or Refractory Neuroblastoma

China
The Second Hospital of Nanjing Medical University

Unknown

A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

Nasopharyngeal Neoplasms

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus (ACT-CAT)

Cytomegalovirus Infection | Adenovirus Infection

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)

Epstein-Barr Virus Infections | Stem Cell Transplant | Cytomegalovirus Infections | Adenovirus Infection

United States
University of Cologne

Unknown

Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides (TECLA)

CD30 Positive Cutaneous T Cell Lymphoma | CD30 Positive Transformed Mycosis Fungoides

Germany
Changzhou No.2 People's Hospital

Not yet recruiting

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Multiple Myeloma

China

Search clinical trials for: T memory cells and NK cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations